Engene Therapeutics Stock Plummets: Can the Company Re‑Build Investor Confidence?
Engene Therapeutics faces steep stock volatility and a negative P/E amid R&D‑heavy healthcare pressures—investors watch how leadership tackles its financial challenges.
2 minutes to read